PITTSBURGH, Nov. 01, 2024 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) (the “Company,” “our” or “us”), a clinical-stage biotechnology company focused on developing innovative therapies for serious diseases with unmet medical needs, today announced that it intends to effect a 1-for-8 reverse stock split of its common stock effective as of 5:00 p.m. Eastern Time on November 7, 2024 upon the filing of a certificate of amendment to the Company’s certificate of incorporation with the Secretary ...

Lipella Pharmaceuticals to Present at 2024 Spartan Capital Investor Conference PITTSBURGH, Pa., Oct. 29, 2024 – PRISM MediaWire – Lipella Pharmaceuticals, Inc. (Nasdaq: LIPO) ("Lipella" or the "Company"), a clinical-stage biotechnology company focused on addressing serious diseases with significant unmet needs, today announced that CEO Jonathan Kaufman, PhD will be presenting at the 2024 Spartan Capital Investor Conference that is being held on November 4, 2024, at the Pierre Hotel in New York. Event: Lipel ...

Lipella Pharmaceuticals Announces U.S. Patent Allowance for Innovative Liposomal Drug Delivery Platform Patent application covers key technology innovations for delivering therapeutic agents Proprietary technology enables precise delivery to improve safety and efficacy in oncology, cancer survivorship and immunotherapy Allowance provides broad IP protection for drug-delivery platform and extends market exclusivity for two lead clinical assets currently in Phase 2 trials PITTSBURGH, PA, October 15, 2024 – PR ...

PITTSBURGH, Oct. 09, 2024 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals, Inc. (Nasdaq: LIPO) ("Lipella" or the "Company"), a clinical-stage biotechnology company focused on addressing serious diseases with significant unmet needs, today announced that CEO Jonathan Kaufman, PhD will be presenting at the 2024 Maxim Healthcare Virtual Summit that is being held on October 15 -17, 2024. Event: Lipella Presentation - 2024 Maxim Healthcare Virtual Summit Date: Thursday, October 17th, 2024 Time: 10:30am Webcast: http ...

NEW YORK, Sept. 25, 2024 (GLOBE NEWSWIRE) -- PRISM MarketView presents an exclusive Q&A with Dr. Michael Chancellor, Co-founder and Chief Medical Officer of Lipella Pharmaceuticals, Inc. (Nasdaq: LIPO). In this interview, Dr. Chancellor provides insights into the company's latest advancements in urological treatments, particularly in recognition of Urology Awareness Month, and discusses the significant progress made in the development of therapies for hemorrhagic cystitis (HC). Lipella Pharmaceuticals, a cl ...

Lipella Pharmaceuticals Reports Encouraging Early Tolerability Results in Phase 2a Trial of LP-310 for Oral Lichen Planus PITTSBURGH, Sept. 24, 2024 – PRISM MediaWire – Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) ("Lipella" or the "Company"), a clinical-stage biotechnology company focused on addressing serious diseases with significant unmet needs, today announced an update on its ongoing multi-center Phase 2a clinical trial evaluating LP-310 for the treatment of Oral Lichen Planus (OLP). The Company report ...

Lipella Pharmaceuticals Launches Innovative Registry to Advance Oral Lichen Planus Research Affecting about 6 million Americans, OLP is a chronic inflammatory disease affecting the mucous membranes of the mouth No FDA-approved therapy currently exists for OLP Patient registry and OLP study information is now available Pittsburgh, PA, August 22, 2024 – Lipella Pharmaceuticals, Inc. (NASDAQ: LIPO) has launched an Oral Lichen Planus (OLP) Patient Registry. This online platform is designed to enhance research a ...

Core Insights - Lipella Pharmaceuticals has introduced LP-20, a novel MRI contrast agent aimed at diagnosing interstitial cystitis and detecting bladder cancer, which will be presented at the 5th International Consultation on Interstitial Cystitis Japan [1][3] Group 1: Product Overview - LP-20 is designed to identify bladder permeability defects and is administered via catheter, utilizing advanced MRI technology to aid in the diagnosis of interstitial cystitis and bladder cancer progression [2][4] - The agent has completed preclinical and proof-of-concept human trials, showing potential as a rapid and cost-effective diagnostic solution [2][4] Group 2: Clinical Significance - The use of LP-20 represents a significant advancement in bladder diagnostics, offering a non-invasive alternative to traditional methods such as cystoscopy [4] - The innovative imaging technique addresses unmet needs in urology, potentially enhancing patient care and streamlining patient identification for clinical trials [3][4] Group 3: Company Background - Lipella Pharmaceuticals is a clinical-stage biotechnology company focused on developing new drugs by reformulating existing generic drugs for new applications, particularly targeting diseases with significant morbidity and mortality [6]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Delaware 20-2388040 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) Title of each class Trading Symbol(s) Name of exchange on which registered Common Stock, par value $0.0001 per share LIPO The Nasdaq Stock Market LLC Large accelerated filer ☐ Accelerated filer ☐ Non-accelerated filer ☒ Smaller reporting company ☒ Emerging growth company ☒ FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUA ...

Lipella Pharmaceuticals Doses First Two Patients in Phase 2a Oral Lichen Planus Clinical Trial Top Line Data Expected Year-End 2024 Pittsburgh, August 12, 2024 — Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) ("Lipella," "our," "us," "we" or the "Company"), a clinical-stage biotechnology company addressing serious diseases with significant unmet need, today announces the dosing of the first two patients with LP-310 in its Phase 2a clinical trial in Oral Lichen Planus (OLP) patients. Lipella's Phase 2a trial is ...